Enterprise
Employer health plan costs to rise despite AI adoption hopes
Global insurer survey reveals AI may identify more health issues requiring treatment, offsetting administrative savings.
Key takeaways
- UK employer health plan costs are forecast to rise 9% in 2027, up from 8% in 2026, according to a Marsh survey of 306 insurers across 69 markets.
- While 55% of insurers expect AI to reduce costs through administrative savings, more than a third worry it will increase spending by detecting more health issues requiring treatment.
- Cancer ranks among the top three causes of claims by value for seven in ten insurers, yet fewer than half typically cover preventive cancer screening.
- The cost of purchasing and implementing AI systems may itself offset potential savings from automation and efficiency gains.
- Earlier cancer detection through screening could reduce need for more complex and expensive treatments, offering potential long-term value despite upfront costs.
Artificial intelligence may not deliver the cost savings employers are hoping for in their healthcare plans, according to a new global survey of insurers that reveals competing pressures on medical spending.
While 55% of insurers expect AI to reduce overall costs of group medical plans over the next two to three years through administrative efficiencies, more than a third anticipate the technology will identify smaller health abnormalities that might otherwise go unnoticed, potentially triggering additional tests and procedures that increase spending.
The findings come from Marsh's Health Trends 2027 report, which surveyed 306 insurers across 69 markets about the factors driving employer-sponsored medical plan costs and strategies for managing health benefit spending.
Costs accelerating in UK and globally
The report forecasts that medical claims costs per person covered by employer-sponsored plans in the UK will rise 9% in 2027, up from 8% in 2026. Globally, the increase is projected at 10.1%, up from 10%, excluding the United States.
These persistent cost increases reflect ongoing pressures even as insurers explore new technologies. Some insurers told Marsh they worry that the expense of purchasing and implementing AI systems could itself drive up overall expenditure.
Cancer drives claims but prevention gaps remain
Cancer emerged as one of the largest sources of claims spending, with seven in ten insurers ranking it among the three leading causes of claims by value in 2025. Yet fewer than half of insurers typically cover preventive cancer screening through employer-sponsored plans, according to the report.
Lorna Friedman, senior partner for health transformation and sustainability at Marsh Health and Benefits, said employers need to consider support across the entire cancer journey, from prevention and screening through treatment, return to work, and ongoing care for survivors.
The report notes that earlier cancer detection can improve outcomes and reduce the need for more complex and expensive treatment, highlighting potential value in prevention and screening programs for both employers and their workforce.
Why it matters
As employers face another year of significant health benefit cost increases, the survey reveals that AI adoption alone won't solve the spending challenge. The technology's ability to detect health issues earlier may actually increase near-term costs, even as it potentially improves long-term outcomes. This dynamic forces benefits leaders to balance cost containment with comprehensive coverage, particularly around high-impact conditions like cancer where prevention gaps persist.
Nick McMenemy, Marsh's UK health and benefits leader, said tackling the causes of poor health earlier, with shared responsibility between the state, employers and individuals, would be key to containing medical trend rates and improving population health.
"The employers that understand their risks and options will be better positioned to manage costs and support their people when it matters most," Friedman said.
The findings were first reported by Healthcare Today based on Marsh's Health Trends 2027 report.